Emerging Growth Opportunities in the US COVID-19 Vaccines and Therapeutics Sector
Agnostic vaccine platform technology enhancing future growth potential of participants in the value chain
Click image to view it in full size
This study by Frost & Sullivan’s Healthcare and Life Sciences team provides critical insights into the US COVID-19 vaccines and therapeutics market, including developing vaccines, supply chain considerations, and requirements to manage distribution. The study also identifies actionable and profitable growth opportunities for industry participants. The US response to the pandemic has been disorganized and made worse with the politicization of vaccine approval and distribution, creating distrust and delaying the country’s vaccination program. Each state in the US has its own vaccination strategy and as such, state health department websites are critical sources of information on when, where, and how to get vaccines.
Maintaining vaccine integrity through all stages of the supply chain requires never-before-seen levels of monitoring and coordination among stakeholders. Partnerships between input supply firms and distributors are as critical as collaborations between vaccine sponsors and contract manufacturers to scale up production for mass immunization.
Take your first step towards achieving growth-centric solutions with our
Growth Pipeline Dialog™. Speak to our industry experts in a complimentary open discussion that will spark innovative thinking and growth opportunities that will benefit your organization.